Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Among authors: hartung hp. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
Interferons in relapsing remitting multiple sclerosis.
Freedman M, King J, Oger J, Sharief M, Hartung HP; PRISMS study investigators. Freedman M, et al. Among authors: hartung hp. Lancet. 2003 May 24;361(9371):1822-3; author reply 1823-4. doi: 10.1016/S0140-6736(03)13419-8. Lancet. 2003. PMID: 12781558 No abstract available.
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.
Frohman EM, Stüve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Frohman EM, et al. Among authors: hartung hp. Arch Neurol. 2005 Oct;62(10):1519-30. doi: 10.1001/archneur.62.10.1519. Arch Neurol. 2005. PMID: 16216934 Review.
Lack of association between antimyelin antibodies and progression to multiple sclerosis.
Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R. Kuhle J, et al. Among authors: hartung hp. N Engl J Med. 2007 Jan 25;356(4):371-8. doi: 10.1056/NEJMoa063602. N Engl J Med. 2007. PMID: 17251533 Free article. Clinical Trial.
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.
Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R; BENEFIT Study Group. Kappos L, et al. Among authors: hartung hp. Lancet. 2007 Aug 4;370(9585):389-97. doi: 10.1016/S0140-6736(07)61194-5. Lancet. 2007. PMID: 17679016 Clinical Trial.
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.
Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA; ICE Study Group. Hughes RA, et al. Among authors: hartung hp. Lancet Neurol. 2008 Feb;7(2):136-44. doi: 10.1016/S1474-4422(07)70329-0. Lancet Neurol. 2008. PMID: 18178525 Clinical Trial.
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group; O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G. O'Connor P, et al. Among authors: hartung hp. Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Lancet Neurol. 2009. PMID: 19729344 Clinical Trial.
1,123 results